The Role of Pharmacomechanical Endovascular Intervention for Iliofemoral Vein Thrombosis Compared to Conventional Anticoagulation Therapy

In-sub Kim and Won-Min Jo

Department of Thoracic and Cardiovascular Surgery, Korea University Ansan Hospital, Ansan, Korea

Received: 7 May 2016
Accepted: 14 September 2016

Address for Correspondence:
Won-Min Jo, MD
Department of Thoracic and Cardiovascular Surgery, Korea University Ansan Hospital, 123, Jeolgup-ro, Danwon-gu, Ansan 15355, Republic of Korea
E-mail: jowonmin@korea.ac.kr

Funding: This work was supported by Korea University Grant (K1609851).

INTRODUCTION

The incidence of first deep vein thrombosis (DVT) in the general population is about 5 per 10,000 person years (1). DVT can lead to pulmonary embolism through multiple mechanisms in the short-term, and chronic venous insufficiency can also be developed from DVT with the incidence of 20%-50% as a long-term sequela (2). Chronic venous insufficiency after a diagnosis of DVT can be defined as post-thrombotic syndrome (PTS). Conventional anticoagulation therapy has been widely used for DVT, and is the recommended primary treatment modality (3,4). However, this treatment has not been associated with the rapid resolution of symptoms or the recanalization of the venous occlusion in more extensive cases, such as in iliofemoral DVT (5,6). Moreover, it is also associated with the long-term disability that accompanies PTS (7). For the more rapid resolution of DVT, several modalities have been introduced, including surgical thrombectomy, catheter-directed thrombolysis, and manual aspiration thrombectomy. Although there have been many studies on the clinical effectiveness of surgical thrombectomy (8,9) and catheter-directed thrombolysis (10,11), there are few reports about the clinical outcomes of manual aspiration thrombectomy combined with the catheter-directed thrombolysis. In this paper, we designed it as a pharmacomechanical endovascular intervention (PMI) (12). Therefore, the aim of our study was to analyze the clinical effectiveness and long-term outcomes of PMI compared to conventional anticoagulant treatment for patients with iliofemoral venous thrombosis.

MATERIALS AND METHODS

Patients

To assess the clinical effectiveness of PMI, we retrospectively reviewed the medical records of patients diagnosed with iliofemoral DVT. Those patients were diagnosed with acute (1 to 14 days) and subacute (15 to 30 days) DVT in our institution regardless of thrombus extension into the below common femoral veins (by duplex ultrasound, computed tomography [CT])...
venography, and conventional venography), from January 2004 to December 2013. To avoid statistical bias, we selected patients with the onset of symptoms within 30 days.

Initially, detailed information regarding the anticoagulant treatment and endovascular treatment were given to all patients, and the patients were selected the modality of treatment by themselves. Patients who were diagnosed with May-Thurner syndrome (MTS) with iliofemoral DVT were excluded. In addition, patients who had any history of surgery within 2 weeks, cerebrovascular accident within 6 months, and severe hypertension, who had a hematologic disorder affecting the coagulation cascade, who had stent insertion only without thrombectomy, and whose DVT was caused by pregnancy or tumor obstruction were also excluded. The included patients were divided into a group that received PMI followed by anticoagulant drugs (PMI group), and a group receiving anticoagulant treatment alone (ACA group). We then compared the risk factors, effectiveness of treatment, morbidity and mortality, residual DVT-free rate, readmission-free rate, and PTS-free rate during the follow-up period. Follow-up was performed at 2 weeks after discharge, and then every 2–3 months thereafter. Duplex ultrasound or CT venography was routinely performed within the initial 6 months and when there was a suspicion about the patency of venous flow.

Anticoagulant therapy (ACA group)
In accordance with the widely-used anticoagulant protocols, intravenous heparin loading and continuous infusion were performed to attain a therapeutic activated partial thromboplastin time (aPTT) that was 1.5–2.5 times the control aPTT (3,4). Anticoagulant therapy was then converted to the oral anticoagulant warfarin with a target international normalized ratio (INR) of 2.0–3.0 in all patients. In 6 patients, an inferior vena cava (IVC) filter was inserted via the right internal jugular vein before intervention. All the IVC filters were removed successfully within 4 weeks after intervention. Venography was performed to determine the extent of the thrombus. A Desilets-Hoffman sheath (COOK, Bloomington, IN, USA), which is an end-hole sheath, was used for aspiration intervention. If the aspiration intervention was difficult, urokinase infusion with a guiding catheter was performed. Urokinase was infused during the procedure in 52 patients (92.9%) in the PMI group, with a mean dosage of 200,000 units (100,000–600,000 units). PMI was repeatedly performed with venography. After the removal of the thrombus from the affected iliofemoral veins, we completed the procedure and maintained a continuous UFH infusion on the general wards. In PMI group, eight patients underwent stent insertion according to the irregularity of the affected iliofemoral vein.

In cases of suspected residual thrombus after PMI, we infused urokinase continuously via the venous sheath overnight. If residual DVT or venous stenosis was diagnosed by duplex ultrasound and CT venography during the admission, we performed a repeat procedure before discharge. All patients took warfarin for at least 6 months, maintaining an INR of 2.0–3.0. We also recommended the use of compression stockings for over 2 years.

Statistical analysis
We used the χ² test to compare categorical variables and the independent sample t-test for continuous variables. Several long-term results during the follow-up period were analyzed by the log-rank test. A P value less than 0.05 was considered to show statistical significance. The analysis was performed using the Statistical Package for Social Sciences (SPSS) software package (Version 22.0; SPSS Inc., Chicago, IL, USA).

Ethics statement
The present study protocol was reviewed and approved by the Institutional Review Board of Korea University Ansan Hospital (IRB No. AS12170). Informed consent was waived by our institutional review board.

RESULTS

Patients’ characteristics
The records of a total of 102 patients (male:female = 53:49; age range, 19–91 years old) were reviewed and divided into PMI (n = 56) and ACA (n = 46) groups. The median follow-up duration was 30.6 months (range 12.3–117.2; interquartile range [IQR] 34.0 months), with no difference between the groups (ACA: median 31.5, range 12.7–117.2, IQR 31.8 months; PMI: median 29.4, range 12.3–104.1, IQR 39.3 months; P = 0.674).

We performed a statistical analysis of sex, age, and body mass index (BMI) between groups. With the exception of age, there was no statistically significant difference between the groups (Table 1). Mean age was higher in the PMI group than in the ACA
Risk factors for DVT, such as chronic renal failure, smoking, trauma, surgery-associated immobilization, malignancy (not directly causing venous occlusion or thrombus), inflammatory bowel disease, history of hormone therapy (including oral contraceptives), and hematologic disease (not affecting the coagulation system such as anemia; \( \times \) Hematologic disease: hematologic disease which did not affect the coagulation system such as anemia; \( ^{\dag} \) Malignancy: malignancy which did not caused direct venous occlusion or thrombus.

Table 1. Comparison of risk factors between two groups

| Risk factors                | ACA (n = 46) | PMI (n = 56) | P value |
|-----------------------------|-------------|--------------|---------|
| Age, yr                     | 52.07 ± 18.00 | 59.53 ± 17.08 | 0.035*  |
| Female, %                   | 43.5        | 51.8         | 0.403   |
| BMI                         | 24.68 ± 2.63 | 25.86 ± 3.99 | 0.102   |
| Chronic renal failure       | 0           | 0            | -       |
| Smoking                     | 13          | 11           | 0.307   |
| Trauma/operation-related immobilization | 13       | 18           | 0.671   |
| Hormone therapy             | 4           | 4            | 0.772   |
| Hematologic disease\(^{\dag}\) | 4         | 2            | 0.274   |
| Malignancy\(\times\)        | 2           | 6            | 0.234   |
| Inflammatory bowel disease  | 1           | 0            | 0.268   |

ACA = anticoagulation treatment only group, PMI = pharmacomechanical endovascular intervention. BMI = body mass index.

*Statistically significant (\( P < 0.05 \)); \(^{\dag}\) Hematologic disease: hematologic disease which did not affect the coagulation system such as anemia; \( ^{\times} \) Malignancy: malignancy which did not caused direct venous occlusion or thrombus.

Table 2. Symptoms duration and involved vein

| All patients | ACA (n = 46) | PMI (n = 56) | P value |
|--------------|-------------|--------------|---------|
| Duration of symptoms, days | 10.87 ± 9.67 | 11.77 ± 8.77 | 0.624   |
| IVC involvement, No. (%) | 2 (4.3) | 9 (16.1) | 0.058   |
| Pulmonary embolism, No. (%) | 10 (21.7) | 5 (8.9) | 0.069   |
| Left side, No. (%) | 22 (47.8) | 33 (58.9) | 0.654   |
| Right side, No. (%) | 23 (50.0) | 22 (39.3) | 0.652   |
| Both sides, No. (%) | 1 (2.2) | 1 (1.8) | 0.891   |

ACA = anticoagulation treatment only group, PMI = pharmacomechanical endovascular intervention, IVC = inferior vena cava.

Group (\( P = 0.035 \)). Risk factors for DVT, such as chronic renal failure, smoking, trauma, surgery-associated immobilization, malignancy (not directly causing venous occlusion or thrombus), inflammatory bowel disease, history of hormone therapy (including oral contraceptives), and hematologic disease (not affecting the coagulation system, including anemia, lupus anticoagulant, hyperesinophilic syndrome, and Behcet’s disease) were assessed in both groups. There was no significant difference in risk factors between the groups (Table 1).

Symptoms duration and diseased vein

The involved veins and the duration of symptoms were compared between the two groups (Table 2). There was no significant difference in the duration of symptoms, rate of IVC involvement, and the incidence of pulmonary embolism. The side of involved veins did not show statistical difference either.

Procedures during the hospital stays

The mean PMI procedure time was 139.63 ± 6.45 minutes (40–300 minutes) and the patients in the PMI group received an IVC filter more often than patients in the ACA group (ACA: n = 6; PMI: n = 36; \( P < 0.001 \)). During PMI, we performed a combined procedure, such as balloon angioplasty (n = 6 [10.7%]) or stent insertion (n = 8 [14.3%]) for fear of re-occlusion. For five patients (8.9%) who had suspected remnant thrombus on final venography, we underwent overnight catheter-directed thrombolysis.

Clinical outcomes during the hospital stays

In PMI group, six patients (10.7%) underwent an additional procedure for a confirmed residual thrombus or venous stenosis during hospitalization. These included thrombectomy (n = 4), balloon angioplasty (n = 3), and stent insertion (n = 3) in the iliac vein. Most additional procedures were performed within 1 week (3.5 ± 1.36 days; range 1–14 days) from the initial procedure day.

There was no morbidity or mortality during hospitalization. Although not significant, the incidence of transfusion was higher in the PMI group, which was due to procedure-related blood loss. Table 3 shows patient hospitalization data.

Follow-up

Follow-up was performed for at least 12 months. During the follow-up, we checked for clinical signs of chronic venous disease using the clinical, etiology, anatomy, and pathophysiology (CEAP) classification system (13). If the clinical classification was changed, we investigated using an imaging study such as CT venography and Doppler sonography. The symptoms on admission were classified as C1 (telangiectasia, n = 1 [2.2%]), C2 (varicose veins, n = 2 [4.3%]), and C3 (edema, n = 44 [95.7%]) in the ACA group and C3 (n = 56 [100%]) in the PMI group. On the first follow-up visit, the clinical signs of CEAP were categorized as C2 (varicose vein, n = 1 [2.2%]) and C3 (edema, n = 17 [37.0%]) in the ACA group and C2 (varicose vein, n = 1 [1.8%]), C3 (edema, n = 11 [19.6%]), and C4a (eczema, n = 1 [1.8%]) in the PMI group. On final follow-up, there were patients with criteria for C2 (varicose vein, n = 1 [2.2%]), C3 (edema, n = 14 [30.4%]), and C4b (lipodermatosclerosis, n = 1 [2.2%]) in the ACA group and C2 (varicose vein n = 1 [1.8%]), C3 (edema, n = 7 [12.5%]), and C6 (active venous ulcer, n = 1 [2.2%]) in the PMI group. At the last follow-up, there were fewer patients with clinical signs of criteria for C3 in the PMI group than in the ACA group (ACA: n = 14; PMI: n = 7; \( P = 0.030 \)). The median duration of taking the oral anticoagulant warfarin was 17.1 months (range 5.8–113.8; IQR 23.3 months) in all patients, with no statistical difference between the groups (ACA: median 16.6, range 6.0–113.8, IQR

https://doi.org/10.3346/jkms.2017.32.1.47

http://jkms.org
Table 4. Causes of readmission

| Causes of readmission | ACA (n = 46) | PMI (n = 56) |
|-----------------------|-------------|-------------|
| Recurrence            | 3 (6.5%)    | 7 (12.5%)   |
| Symptom aggravation   | 2 (4.3%)    | 1 (1.8%)    |
| Stent related recurrence | 0          | 3 (5.4%)   |
| Bleeding              | 0           | 3 (5.4%)    |
| Readmission (Total)   | 5 (10.9%)   | 11 (19.6%)  |

Values are presented as number (%).
ACA = anticoagulation treatment only group, PMI = pharmacomechanical endovascular intervention.

Readmission rates during the follow-up period

The log-Rank test for the readmission-free rate in the two groups is shown in Fig. 1, with no statistical significance between the groups ($P = 0.221$). The 1-, 3-, and 5-year readmission-free rates were 91.3%, 88.8%, and 88.8% in the ACA group and 85.7%, 81.5%, and 74.7% in the PMI group, respectively. Although the readmission-free rate did not show statistical significance, the ACA group had a lower incidence of readmission than the PMI group. The causes of readmission are described in Table 4. The recurrence rate was higher in the PMI group because stent-related recurrences were included in the rate. There were no significant episodes of bleeding during the follow-up period except for isolated episodes of gum bleeding and anal bleeding.

Residual DVT during the follow-up period

In this study, we defined ‘residual DVT’ as remnant thrombus in the deep vein above femoral vein level at final evaluation regardless of partial or total occlusion. The percentage of patients who did not experience a residual thrombus during the 5-year follow-up period is shown in Fig. 2. The 1-, 3-, and 5-year residual DVT-free rates did not show statistical significance between the two groups (ACA: 84.7%, 71.6%, and 46.0%; PMI: 82.1%, 76.8%, and 76.8%, respectively; $P = 0.235$). After 3 years of follow-up, patients in the PMI had a higher likelihood of not experiencing residual DVT. Because we diagnosed the residual DVT without intravascular ultrasound (IVUS) at final imaging evaluation, this can be a limitation in this study.

Chronic deep venous changes: PTS

The diagnosis of PTS can be ambiguous because the symptoms of PTS can range from mild to severe. In this study, we defined PTS by the chronic venous insufficiency symptoms and signs (based on the CEAP classification, C1–6) with venous flow abnormalities (confirmed by diagnostic studies such as ultrasound, venography, and CT venography). Although residual DVT, venous collateral flow, venous reflux and venous fibrosis were regarded as confirmatory findings of PTS, a patient who had these confirmatory findings without clinical symptoms and signs was not categorized as having PTS. The same definition is applied in reverse.

The PMI group had a significantly higher rate of patients without PTS ($P = 0.019$). The 1-, 3-, and 5-year PTS-free rates were 93.5%, 74.0%, and 55.7% in the ACA group and 92.9%, 90.0%, and 90.0% in the PMI group, respectively (Fig. 3). The study findings are listed in Table 5. We adjusted the PTS-free rate with a Cox-regression model, and the results showed that the rate of patients without PTS was significantly higher in the PMI group as compared to the ACA group ($P = 0.047$).
DISCUSSION

Despite its long history in the medical literature, the etiology of venous thrombosis was only elucidated in 1856 by Virchow and Sevitt (14,15), and the treatment of DVT began relatively recently in the 1930s (16). Current guidelines for the treatment of DVT of the lower extremities recommend anticoagulant therapy for the prevention of thrombus extension, pulmonary embolism, and PTS. Recent antithrombotic guidelines from the American College of Chest Physicians (ACCP) recommend anticoagulant therapy alone over catheter-directed thrombolysis, systemic thrombolysis, and operative venous thrombolysis for acute proximal DVT (17). The American Heart Association (AHA) also recommends anticoagulation as the primary treatment for iliofemoral DVT (18). Although the AHA suggested preventive strategies for PTS in 2014, the fundamental principles were based on appropriate anticoagulation treatment.

The supplementary use of catheter-directed thrombolysis, pharmacomechanical thrombolysis, and surgical thrombectomy for DVT treatment and/or the prevention of PTS should only be considered in selected patients and performed at specialized centers (2). Catheter-directed thrombolysis was recommended in select patients in a review by Gogalniceanu et al. (19). Those authors suggested that the combination of catheter-directed thrombolysis and thrombectomy might be superior to anticoagulant therapy with regards to PTS progression. However, Karthikesalingam and colleagues (12) did not show that percutaneous mechanical thrombectomy had increased effectiveness in PTS prevention.

PTS, the most common long-term complication of DVT (20), is a spectrum of symptoms, ranging from minor leg swelling to severe symptoms such as debilitating leg pain, intractable edema, and leg ulceration (21). Reduced quality of life and increased healthcare costs are some of the long-term concerns due to DVT-induced PTS (22,23). Kahn and colleagues (20) identified the predictors of severe PTS, including iliac and femoral vein involvement and the persistence of symptoms after 1 month of treatment. Thus, for more rapid resolution of DVT, other therapies such as systemic thrombolysis, surgical thrombectomy, catheter-directed thrombolysis, and thrombectomy have been introduced (24). Because of excessive bleeding risk and the high failure rate of lysis, the use of systemic thrombolysis has transitioned to catheter-directed thrombolysis (6,25).

In our opinion, PMI is more time-effective modality in removing thrombus than thrombolysis. In addition, this is also safe procedure. In fact, many studies have reported on the effectiveness of catheter-directed techniques, but few have considered PMI. In addition, the long-term clinical outcomes about PMI with anticoagulation have rarely been reported. Therefore, in this study, we aimed to compare the long-term treatment results and prevalence of PTS after the treatment of acute and subacute iliofemoral DVT with PMI and ACA. According to a multicenter cohort study by Kahn, about 30% of DVT patients

Table 5. Study findings of PTS

| Findings                        | ACA | PMI |
|---------------------------------|-----|-----|
| Residual DVT                    | 7   | 2   |
| Chronic venous change           | 6   | 1   |
| Stent thrombosis                | 0   | 1   |
| Stent compression               | 0   | 1   |

PTS = post-thrombotic syndrome, ACA = anticoagulation treatment only group, PMI = pharmacomechanical endovascular intervention, DVT = deep vein thrombosis.
develop mild PTS, and 13% of DVT patients have moderate to severe PTS. Although the ACCP and AHA guidelines suggest anticoagulation therapy, we hypothesized that treatment with PMI may have several advantages for the early resolution of DVT in selected patients, as described above. Sevitt (15) revealed that a partial resolution of DVT in many patients in the ACA group was noted during follow-up, but recovery of normal physiologic venous function after anticoagulant treatment was rare. Furthermore, residual thrombus after catheter-directed thrombolysis is correlated with recurrent DVT (26). Although this study had some limitations that we did not use IVUS for the diagnosis of residual DVT and did not subdivide the data whether patients have a thrombus in deep vein below femoral level or not, our data revealed that the residual DVT-free rates and readmission-free rates were not differ between the groups. However, the percentage of patients who did not experience PTS was higher in the PMI group than in the ACA group during the 5-year follow-up period. The pathophysiology of PTS progression is hypothesized to be due to damage to venous valves by thrombi or thrombus-induced inflammatory mediators with residual venous obstruction, leading to increased venous pressure (16). Thus, the complete reversal of DVT within the first month of its diagnosis is very important. According to this study, the use of PMI in addition to ACA may be more effective for PTS prevention than ACA alone. Because our study was a retrospective study with small number of patients, we could not match the symptoms with the Villalta scale (27), but just applied the CEAP classification with venous flow abnormalities for PTS diagnosis. This is another limitation of our study. In addition, we prescribed anticoagulation longer periods than AHA guidance. Although we did not have any experience of complication due to the long-term use of anticoagulant agent, we cannot completely rule out the possibility of the effects of long-term anticoagulation treatment on the role of PTS prevention.

In conclusion, although PMI is invasive, we did not encounter serious morbidity or mortality according to the procedures. In addition, our study revealed that PMI decreased the PTS incidence during the entire follow-up period. Therefore, we suggest that clinicians consider PMI as an effective modality of therapy for acute and subacute iliofemoral DVTs.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Research conception and design: Jo WM. Data analysis and interpretation: Kim IS. Statistical analysis: Kim IS. Drafting of the manuscript: Kim IS. Critical revision of the manuscript: Jo WM. Receiving grant: Jo WM. Approval of final manuscript: all authors.

ORCID

In-sub Kim http://orcid.org/0000-0002-1773-0072
Won-Min Jo http://orcid.org/0000-0002-0082-0098

REFERENCES

1. Fowkes FJ, Price JE, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003; 25: 1–5.
2. Kahn SR, Comerota AJ, Cashman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130: 1636-61.
3. Hull RD, Raskob GE, Rosenholm D, Lemaire J, Pimeo GE, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-95.
4. Raschke RA, Reilly BM, Guidry JR, Fontana JA, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-81.
5. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Scannapieco G, Ambrosio GB, Pesavento R, Cappini S, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150: 577-85.
6. Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg 1993; 36: 359-64.
7. Prandoni P, Frulla M, Sartor D, Concolato A, Girolami A. Vein abnormalities and the post-thrombotic syndrome. J Thromb Haemost 2005; 3: 401-2.
8. Plate G, Eklöf B, Norgren L, Ohlin P, Dahlström JA. Venous thrombectomy for iliofemoral vein thrombosis–10-year results of a prospective randomised study. Eur J Vasc Endovasc Surg 1997; 14: 367-74.
9. Gänger KH, Nachbur BH, Ris HB, Zurnbigg H. Surgical thrombectomy versus conservative treatment for deep venous thrombosis; functional comparison of long-term results. Eur J Vasc Surg 1989; 3: 529–38.
10. Enden T, Klov NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsaal G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, et al. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost 2009; 7: 1268-75.
11. Dasari TW, Pappy R, Hennebry TA. Pharmacomechanical thrombolysis of acute and chronic symptomatic deep vein thrombosis: a systematic review of literature. Angiology 2012; 63: 138-45.
12. Karthikesalingam A, Young EL, Hinchliffe RJ, Loftus IM, Thompson MM, Holt PJ. A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2011; 41: 554-65.
13. Kistner RL, Eklöf B, Masuda EM. Diagnosis of chronic venous disease of the lower extremities: the “CEAP” classification. Mayo Clin Proc 1996; 71: 338-45.
14. Virchow R. Thrombosis and Emboli (1846-1856). Canton, MA: Science History Publications, 1998.
15. Sevitt S. Pathology and pathogenesis of deep vein thrombi. *Proc R Soc Med* 1975; 68: 261.
16. Mannucci PM, Poller L. Venous thrombosis and anticoagulant therapy. *Br J Haematol* 2001; 114: 258-70.
17. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012; 141: e152S-e184S.
18. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation* 2011; 123: 1788-830.
19. Gogalniceanu P, Johnston CJ, Khalid U, Holt PJ, Hinchcliffe R, Loftus IM, Thompson MM. Indications for thrombolysis in deep venous thrombosis. *Eur J Vasc Endovasc Surg* 2009; 38: 192-8.
20. Kahn SR, Shrier I, Julian JA, Ducruet T, ArsenaULT A, Miron MJ, Roussin A, DesmaraIS S, Joly F, Kassis J, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Ann Intern Med* 2008; 149: 698-707.
21. Kurz X, Kahn SR, Abenhaim L, Clement D, Norgren L, Baccaglini U, Bernard A, Cooke JP, Cornu-Thenard A, Depaivre M, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous insufficiency epidemiologic and economic studies. *Int Angiol* 1999; 18: 83-102.
22. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. *Arch Intern Med* 2002; 162: 1144-8.
23. Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. *Lancet* 1997; 349: 759-62.
24. Comerota AJ, Paolini D. Treatment of acute iliofemoral deep venous thrombosis: a strategy of thrombus removal. *Eur J Vasc Endovasc Surg* 2007; 33: 351-60.
25. Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis. *Cochrane Database Syst Rev* 2004: CD002783.
26. Aziz F, Comerota AJ. Quantity of residual thrombus after successful catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with recurrence. *Eur J Vasc Endovasc Surg* 2012; 44: 210-3.
27. Villalta S, Bagatella P, Piccioni A, Lensing AW, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. *Haemostasis* 1994; 24: 138a.